<DOC>
	<DOCNO>NCT00110344</DOCNO>
	<brief_summary>This study design study patient diagnose advanced renal cell cancer primary tumor place .</brief_summary>
	<brief_title>Research Study Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Life expectancy least 12 week Clinical , radiographic , pathologic diagnosis metastatic renal cell carcinoma ( RCC ) . All renal cell histology allow Acceptable surgical risk judgment study investigator consult urological surgeon At least one unidimensional measurable lesion outside plan nephrectomy specimen Patients ECOG performance status 0 1 History bleed diathesis unexpected surgical bleeding Patients currently receive treatment requirement therapeutic anticoagulation Prior therapy RCC . Palliative radiation therapy painful unstable bone metastasis permit provide measurable metastatic disease outside radiation field Known history HIV infection Symptomatic metastatic brain meningeal tumor , unless patient &gt; 6 month definitive therapy , CT MRI scan within 6 week study entry negative brain metastasis clinically stable respect tumor time study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Cancer</keyword>
</DOC>